BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 34975879)

  • 21. Increased PSA expression on prostate cancer exosomes in in vitro condition and in cancer patients.
    Logozzi M; Angelini DF; Iessi E; Mizzoni D; Di Raimo R; Federici C; Lugini L; Borsellino G; Gentilucci A; Pierella F; Marzio V; Sciarra A; Battistini L; Fais S
    Cancer Lett; 2017 Sep; 403():318-329. PubMed ID: 28694142
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Additional value of the ratio of serum total testosterone to total prostate-specific antigen in the diagnosis of prostate cancer in a Chinese population.
    Xu L; Hu X; Zhu Y; Lu J; Xu Y; Wang G; Guo J
    Andrologia; 2018 Mar; 50(2):. PubMed ID: 28752596
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A "PSA pyramid" for men with initial prostate-specific antigen ≤3 ng/ml: a plea for individualized prostate cancer screening.
    Randazzo M; Beatrice J; Huber A; Grobholz R; Manka L; Chun FK; Recker F; Kwiatkowski M
    Eur Urol; 2015 Oct; 68(4):591-7. PubMed ID: 24794075
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication.
    Vickers A; Cronin A; Roobol M; Savage C; Peltola M; Pettersson K; Scardino PT; Schröder F; Lilja H
    J Clin Oncol; 2010 May; 28(15):2493-8. PubMed ID: 20421547
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial.
    Cappuccini F; Bryant R; Pollock E; Carter L; Verrill C; Hollidge J; Poulton I; Baker M; Mitton C; Baines A; Meier A; Schmidt G; Harrop R; Protheroe A; MacPherson R; Kennish S; Morgan S; Vigano S; Romero PJ; Evans T; Catto J; Hamdy F; Hill AVS; Redchenko I
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32591433
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prostate-specific antigen (PSA) testing of men in UK general practice: a 10-year longitudinal cohort study.
    Young GJ; Harrison S; Turner EL; Walsh EI; Oliver SE; Ben-Shlomo Y; Evans S; Lane JA; Neal DE; Hamdy FC; Donovan JL; Martin RM; Metcalfe C
    BMJ Open; 2017 Oct; 7(10):e017729. PubMed ID: 29084797
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Age-Adjusted PSA Levels in Prostate Cancer Prediction: Updated Results of the Tyrol Prostate Cancer Early Detection Program.
    Heidegger I; Fritz J; Klocker H; Pichler R; Bektic J; Horninger W
    PLoS One; 2015; 10(7):e0134134. PubMed ID: 26218594
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination of Prostate Cancer Antigen 3 and Prostate-Specific Antigen Improves Diagnostic Accuracy in Men at Risk of Prostate Cancer.
    Cao L; Lee CH; Ning J; Handy BC; Wagar EA; Meng QH
    Arch Pathol Lab Med; 2018 Sep; 142(9):1106-1112. PubMed ID: 29547000
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Performance of a neural network in detecting prostate cancer in the prostate-specific antigen reflex range of 2.5 to 4.0 ng/mL.
    Babaian RJ; Fritsche H; Ayala A; Bhadkamkar V; Johnston DA; Naccarato W; Zhang Z
    Urology; 2000 Dec; 56(6):1000-6. PubMed ID: 11113747
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
    Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
    Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characteristics of Prostate Cancer by Opportunistic Screening in Korean Men with a Prostate-Specific Antigen Level Less Than 4.0 ng per Milliliter.
    Choi H; Cho S; Bae JH; Lee SE; Hong SK; Moon DG; Cheon J; Byun SS; Park JY
    Urol Int; 2017; 99(2):143-148. PubMed ID: 28395285
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive value of prostate specific antigen in a European HIV-positive cohort: does one size fit all?
    Shepherd L; Borges ÁH; Ravn L; Harvey R; Bower M; Grulich A; Silverberg M; Kronborg G; Galli M; Kirk O; Lundgren J; Mocroft A;
    Antivir Ther; 2016; 21(6):529-534. PubMed ID: 26823399
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inverse association between histologic inflammation in needle biopsy specimens and prostate cancer in men with serum PSA of 10-50 ng/mL.
    Terakawa T; Miyake H; Kanomata N; Kumano M; Takenaka A; Fujisawao M
    Urology; 2008 Dec; 72(6):1194-7. PubMed ID: 18829081
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis.
    Louie KS; Seigneurin A; Cathcart P; Sasieni P
    Ann Oncol; 2015 May; 26(5):848-864. PubMed ID: 25403590
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
    Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
    BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictive value of four kallikrein markers for pathologically insignificant compared with aggressive prostate cancer in radical prostatectomy specimens: results from the European Randomized Study of Screening for Prostate Cancer section Rotterdam.
    Carlsson S; Maschino A; Schröder F; Bangma C; Steyerberg EW; van der Kwast T; van Leenders G; Vickers A; Lilja H; Roobol MJ
    Eur Urol; 2013 Nov; 64(5):693-9. PubMed ID: 23683475
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The roles of MRI-based prostate volume and associated zone-adjusted prostate-specific antigen concentrations in predicting prostate cancer and high-risk prostate cancer.
    Zheng S; Jiang S; Chen Z; Huang Z; Shi W; Liu B; Xu Y; Guo Y; Yang H; Li M
    PLoS One; 2019; 14(11):e0218645. PubMed ID: 31743339
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prebiopsy Biparametric Magnetic Resonance Imaging Combined with Prostate-specific Antigen Density in Detecting and Ruling out Gleason 7-10 Prostate Cancer in Biopsy-naïve Men.
    Boesen L; Nørgaard N; Løgager V; Balslev I; Bisbjerg R; Thestrup KC; Jakobsen H; Thomsen HS
    Eur Urol Oncol; 2019 May; 2(3):311-319. PubMed ID: 31200846
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improving prostate cancer detection in veterans through the development of a clinical decision rule for prostate biopsy.
    Hill OT; Mason TJ; Schwartz SW; Foulis PR
    BMC Urol; 2013 Jan; 13():6. PubMed ID: 23356551
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel algorithm for the prediction of prostate cancer in clinically suspected patients.
    Gallotta A; Ziglioli F; Ferretti S; Maestroni U; Moretti M; Aloe R; Gnocchi C; Di Palo M; Fassina G
    Cancer Biomark; 2013; 13(4):227-34. PubMed ID: 24240583
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.